Synopsis:
Cohance Lifesciences Ltd. (formerly Suven Pharmaceuticals) has unveiled two strategic investments aimed at strengthening its presence in high-growth therapeutic modalities USD 10 million for cGMP bioconjugation expansion at its U.S. arm NJ Bio and Rs. 230 million for a new cGMP oligonucleotide facility in Hyderabad, India.
Cohance Lifesciences announces USD 10 mn Investment in cGMP Bioconjugation Suite at NJ Bio, Princeton, NJ, U.S. to Accelerate ADC Innovation. Also announces Rs. 230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India.
With market capitalization of Rs. 37,448 cr, the shares of Cohance Lifesciences Ltd are currently trading at Rs. 981 apiece, gaining nearly 4% in today’s market, making a high of Rs. 985.75 from its previous of Rs. 950.75 apiece.
News
Cohance Lifesciences Ltd. (formerly Suven Pharmaceuticals) has announced two major capacity expansion projects. The company will invest USD 10 million in its U.S. subsidiary, NJ Bio, to set up a state-of-the-art cGMP bioconjugation suite in Princeton, capable of producing up to 2 kg of Antibody-Drug Conjugates (ADCs) for clinical supply up to Phase 2b, operational by Q4 FY26.
In India, it will invest Rs. 230 million to build a cGMP oligonucleotide building block facility in Hyderabad with 700 kg annual capacity, advanced cleanroom systems, and scalability from R&D to commercial production. Validations are expected by CY26.
These moves strengthen Cohance’s global footprint in high-growth modalities, building on FY25 revenue of Rs. 26 billion (~USD 313 million) and 33.6% EBITDA margins.
Also read: Wastewater management stock jumps after announcing its June quarter results
Financial highlights
Cohance Lifesciences reported a strong FY25 performance with revenue rising 9.1% YoY to Rs. 2,610.3 crore. Adjusted EBITDA grew 2.9% to Rs. 878.1 crore, maintaining a healthy 31.3% margin, while PAT declined 4.8% to Rs. 546.3 crore due to higher depreciation and finance costs.
- The combined balance sheet remained net cash positive at Rs. 35.8 crore, despite capex and two acquisitions during the year, reflecting disciplined capital allocation and strong internal accruals.
- Fixed assets increased to Rs. 2,120 crore, driven by strategic investments in capacity expansion across key growth areas and integration of acquired platforms.
- Total borrowings reduced to Rs. 260 crore, while liquidity remained strong with cash and equivalents at Rs. 290 crore.
Cohance Lifesciences Ltd. (formerly Suven Pharmaceuticals) is a contract development and manufacturing organization (CDMO) that offers end-to-end solutions for global pharma and biotech companies.
The company specializes in small molecules, specialty chemicals, and high-growth drug modalities like Antibody-Drug Conjugates (ADCs) and oligonucleotides, providing integrated services from R&D and process development to large-scale commercial manufacturing, with a strong focus on complex and niche therapies.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
